Cannabis Ruderalis – Thought to be a cannabis species originating in central Asia, it flowers earlier, is much smaller, and can withstand much harsher climates than either Cannabis indica or Cannabis sativa. This species purportedly buds based on age rather than changes in length of daylight, known as auto-flowering. It’s used primarily for food production, such as hemp seeds and hemp seed oil.

An alternative to the gateway hypothesis is the common liability to addiction (CLA) theory. It states that some individuals are, for various reasons, willing to try multiple recreational substances. The "gateway" drugs are merely those that are (usually) available at an earlier age than the harder drugs. Researchers have noted in an extensive review that it is dangerous to present the sequence of events described in gateway "theory" in causative terms as this hinders both research and intervention.[271]
I strongly agree they really are greedy and money hungry. Isn’t it always funny how the big ones fall sooner or later? The government can’t have everything, there are just some things that belong to the people. Medicine plants in general have been around since the start of creation, and it looks like we’re just finding out which ones they are. Our forefathers know which ones they were and they knew how to use them but it’s been a forgotten skill some generations have forgotten since modern medicine took over. That’s not right. I saw some articles where the government was going to try to once again outlaw hemp and cannabis. I say if you really want some before it’s outlawed, grab up as much as you can and hide it somewhere good where no one but you can ever find it. I would highly recommend putting it in an airtight container with as many other airtight layers around it as possible. That way, it will never be found by anyone who’s not supposed to find it. The best advantage is to have enough handy to take care of yourself for life while everyone not in on ditching big Pharma is dying. If hamper and cannabis are outlawed, only the elite will be the ones still standing in the end
^ Gobbi, Gabriella; Atkin, Tobias; Zytynski, Tomasz; Wang, Shouao; Askari, Sorayya; Boruff, Jill; Ware, Mark; Marmorstein, Naomi; Cipriani, Andrea; Dendukuri, Nandini; Mayo, Nancy (13 February 2019). "Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood". JAMA Psychiatry. doi:10.1001/jamapsychiatry.2018.4500. Retrieved 13 February 2019.
Wild North American hemp is derived mostly from escaped European cultivated hemp imported in past centuries, perhaps especially from a revival of cultivation during World War II. Wild Canadian hemp is concentrated along the St. Lawrence and lower Great Lakes, where considerable cultivation occurred in the 1800s. In the US, wild hemp is best established in the American Midwest and Northeast, where hemp was grown historically in large amounts. Decades of eradication have exterminated many of the naturalized populations in North America. In the US, wild plants are rather contemptuously called “ditch weed” by law enforcement personnel. However, the attempts to destroy the wild populations are short-sighted, because they are a natural genetic reservoir, mostly low in THC. Wild North American plants have undergone many generations of natural adaptation to local conditions of climate, soil and pests, and accordingly it is safe to conclude that they harbor genes that are invaluable for the improvement of hemp cultivars. We have encountered exceptionally vigorous wild Canadian plants (Fig. 52), and grown wild plants from Europe (Fig. 53) which could prove valuable. Indeed, studies are in progress in Ontario to evaluate the agronomic usefulness of wild North American hemp. Nevertheless, present policies in North America require the eradication of wild hemp wherever encountered. In Europe and Asia, there is little concern about wild hemp, which remains a valuable resource.
In 1988, the first cannabinoid receptor was identified (CB1) (Howlett et al 1988) and in 1993, a second was described (CB2) (Munro et al 1993). Both are 7-domain G-protein coupled receptors affecting cyclic-AMP, but CB1 is more pervasive throughout the body, with particular predilection to nociceptive areas of the central nervous system and spinal cord (Herkenham et al 1990; Hohmann et al 1999), as well as the peripheral nervous system (Fox et al 2001; Dogrul et al 2003) wherein synergy of activity between peripheral and central cannabinoid receptor function has been demonstrated (Dogrul et al 2003). CB2, while commonly reported as confined to lymphoid and immune tissues, is also proving to be an important mediator for suppressing both pain and inflammatory processes (Mackie 2006). Following the description of cannabinoid receptors, endogenous ligands for these were discovered: anandamide (arachidonylethanolamide, AEA) in 1992 in porcine brain (Devane et al 1992), and 2-arachidonylglycerol (2-AG) in 1995 in canine gut tissue (Mechoulam et al 1995) (Figure 1). These endocannabinoids both act as retrograde messengers on G-protein coupled receptors, are synthesized on demand, and are especially active on glutamatergic and GABA-ergic synapses. Together, the cannabinoid receptors, their endogenous ligands (“endocannabinoids”) and metabolizing enzymes comprise the endocannabinoid system (ECS) (Di Marzo et al 1998), whose functions have been prosaically termed to be “relax, eat, sleep, forget and protect” (p. 528). The endocannabinoid system parallels and interacts at many points with the other major endogenous pain control systems: endorphin/enkephalin, vanilloid/transient receptor potential (TRPV), and inflammatory. Interestingly, our first knowledge of each pain system has derived from investigation of natural origin analgesic plants, respectively: cannabis (Cannabis sativa, C. indica) (THC, CBD and others), opium poppy (Papaver somniferun) (morphine, codeine), chile peppers (eg, Capsicum annuum, C. frutescens, C. chinense) (capsaicin) and willow bark (Salix spp.) (salicylic acid, leading to acetylsalicylic acid, or aspirin). Interestingly, THC along with AEA and 2-AG, are all partial agonists at the CB1 receptor. Notably, no endocannabinoid has ever been administered to humans, possibly due to issues of patentability and lack of commercial feasibility (Raphael Mechoulam, pers comm 2007). For an excellent comprehensive review of the endocannabinoid system, see Pacher et al (2006), while Walker and Huang have provided a key review of antinociceptive effects of cannabinoids in models of acute and persistent pain (Walker and Huang 2002).
Consumers report using CBD for a huge variety of health and wellness reasons, but a lot more research is needed to determine which symptoms and ailments it works best for. Currently, there are more than 40 clinical trials enrolling patients to examine the effectiveness of CBD for a variety of diseases, including substance use disorder, chronic pain, post-traumatic stress disorder (PTSD), depression, schizophrenia, and many others. Most importantly, CBD is incredibly safe, and not addictive. Even young children can tolerate daily doses of up to twenty milligrams (20 mg) per kilogram (1 kg) of body weight (for a 175 pound adult, that’s more than 1,500 mg). The most common side effect of high-dose CBD is sleepiness.
Despite its centrality in human cultures across the globe, the European taxonomists who bequeathed Cannabis sativa its name didn’t quite get it right. When Carolus Linneaus came to naming the marijuana plant’s genus, he thought there was only one species, instead of the three we now know exist. Hence the confusion surrounding the fact that there are three distinct species of the genus Cannabis sativa, one of which is the sativa species. 

CBD Pain